| 1 |
7,335,748 |
|
RG1 antibodies and uses thereof |
| 2 |
7,332,332 |
|
Buffer solution for electroporation and a method comprising the use of the same |
| 3 |
7,320,859 |
|
Modular transfection systems |
| 4 |
7,312,032 |
|
Methods for screening ligands that activate the translocation of a steroid receptor to the nucleus in mammalian cells |
| 5 |
7,311,910 |
|
Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions |
| 6 |
7,307,154 |
|
DNA encoding a novel RG1 polypeptide |
| 7 |
7,304,033 |
|
Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
| 8 |
7,300,915 |
|
Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| 9 |
7,300,761 |
|
Methods and device for detecting prostate specific antigen (PSA) |
| 10 |
7,183,255 |
|
Method for stabilizing blood pressure in hemodialysis subjects |
| 11 |
7,048,928 |
|
Anti-allergic pharmaceutical composition containing at least one allergen and at least one antihistamine compound |
| 12 |
7,030,232 |
|
E25A protein, methods for producing and use thereof |
| 13 |
6,906,026 |
|
Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 14 |
6,899,895 |
|
Lamellar gels and methods for making and regulating |
| 15 |
6,858,150 |
|
Water processing device with liquid seal |
| 16 |
6,838,081 |
|
Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient |
| 17 |
6,830,937 |
|
Method for generating and identifying antibodies directed against a B7 |
| 18 |
6,777,231 |
|
Adipose-derived stem cells and lattices |
| 19 |
6,764,825 |
|
Methods and device for detecting prostate specific antigen (PSA) |
| 20 |
6,756,036 |
|
Methods for treating cancer using PSCA antibodies and fragments thereof |
| 21 |
6,686,196 |
|
Recombinant, modified adenoviral vectors for tumor specific gene expression and uses thereof |
| 22 |
6,666,684 |
|
Impression and foundation system for implant-supported prosthesis |
| 23 |
6,663,858 |
|
In Vivo gene transfer using implanted retroviral producer cells |
| 24 |
6,663,857 |
|
In vivo gene transfer using implanted retroviral producer cells |
| 25 |
6,663,770 |
|
Water processing device |
| 26 |
6,645,728 |
|
Inhibitor of the inflammatory response induced by TNF.alpha. and IL-1 |
| 27 |
6,641,809 |
|
Method of regulating cellular processes mediated by B7 and CD28 |
| 28 |
6,627,200 |
|
Utilization of CD 137 in order to promote the proliferation of peripheral monocytes |
| 29 |
6,623,940 |
|
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| 30 |
6,609,017 |
|
Processed neural signals and methods for generating and using them |
| 31 |
6,565,889 |
|
Bilayer structure which encapsulates multiple containment units and uses thereof |
| 32 |
6,541,212 |
|
Methods for detecting prostate stem cell antigen protein |
| 33 |
6,521,615 |
|
Diagnosing an animal for pyrophosphate gout, osteoporosis, or osteoarthritis by assaying intracellular pyrophosphate content in peripheral blood cells |
| 34 |
6,521,456 |
|
Cellular transport system for the transfer of a nucleic acid through the nuclear envelope and methods thereof |
| 35 |
6,517,839 |
|
Methods for inducing interleukin-12 and a type1/Th1 T-cell response |
| 36 |
6,465,627 |
|
DAX-1 protein, methods for production and use thereof |
| 37 |
6,455,300 |
|
Method and compositions for monitoring DNA binding molecules in living cells |
| 38 |
6,455,250 |
|
Endonuclease compositions and methods of use |
| 39 |
6,365,797 |
|
Mice models of human prostate cancer progression |
| 40 |
6,365,347 |
|
Method for identifying disruptors of biological pathways using genetic selection |
| 41 |
6,365,338 |
|
Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source |
| 42 |
6,358,523 |
|
Macromolecule-lipid complexes and methods for making and regulating |
| 43 |
6,316,258 |
|
Methods for preventing and treating fibrotic diseases resulting from accumulation of excess extracellular matrix induced by TGF.beta. using renin inhibitors |
| 44 |
6,267,960 |
|
PSCA: prostate stem cell antigen |
| 45 |
6,265,538 |
|
Inhibitor of the inflammatory response induced by the TNFA and IL-1 |
| 46 |
6,261,791 |
|
Method for diagnosing cancer using specific PSCA antibodies |
| 47 |
6,261,789 |
|
Methods for detecting the presence of a PSCA protein using PSCA antibodies |
| 48 |
6,258,939 |
|
PSCA antibodies and hybridomas producing them |
| 49 |
6,228,646 |
|
Helper-free, totally defective adenovirus for gene therapy |
| 50 |
6,221,861 |
|
Reducing pyrophosphate deposition with calcium antagonists |
| 51 |
6,221,401 |
|
Bilayer structure which encapsulates multiple containment units and uses thereof |
| 52 |
6,207,186 |
|
Lamellar gels and methods for making and using |
| 53 |
6,169,176 |
|
Deoxynucleic alkyl thiourea compounds and uses thereof |
| 54 |
6,136,965 |
|
Deoxynucleic alkyl and alkoxy thiourea compounds |
| 55 |
6,111,071 |
|
Recombinant fusion protein comprising PDC-E2, BCOADC-E2 and OGDC-E2 and uses thereof |
| 56 |
6,110,702 |
|
PSA positive regulating (PSAR) sequences and uses thereof |
| 57 |
6,107,540 |
|
Mice models of human prostate cancer progression |
| 58 |
6,093,800 |
|
E25a protein, methods for production and use thereof |
| 59 |
6,090,914 |
|
CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| 60 |
6,056,547 |
|
Impression and foundation system for implant-supported prosthesis |
| 61 |
6,030,830 |
|
Immunoglobulin trans-spliced transcripts and uses thereof |
| 62 |
6,013,785 |
|
Polynucleoside chain having multiple ribonucleosides, the nucleosides coupled by guanidyl linkages |
| 63 |
5,993,800 |
|
Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
| 64 |
5,977,318 |
|
CTLA4 receptor and uses thereof |
| 65 |
5,968,510 |
|
CTLA4 receptor and uses thereof |
| 66 |
5,919,652 |
|
Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
| 67 |
5,916,560 |
|
Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith |
| 68 |
5,885,579 |
|
CTLA4 receptor and uses thereof |
| 69 |
5,824,655 |
|
Anti-transforming growth factor-.beta. gene therapy |
| 70 |
5,773,253 |
|
MYPPPY variants of CTL A4 and uses thereof |
|
